Moderna reported a profit of $217 million in the three months ending Dec. 31. Moderna said Tuesday that its updated COVID-19 ...
Blackstone Life Sciences, a private investment company, is making a big bet on its Cambridge neighbor Moderna, the drug firm that has made multiple versions of a vaccine to fend off COVID-19.
Think it's time for a booster? Moderna says its newest COVID vaccine is showing signs of a stronger immune response against the virus than the current shot being offered and a longer shelf-life.
Moderna Inc. says the newest version of its Covid-19 vaccine could have a longer shelf life than previous iterations — and new data shows it also produces a better immune response. The Cambridge ...
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.
Pfizer Inc. and Moderna Inc. have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported on Sunday. The new price for the Pfizer ...
The safety profile of mRNA-1283 was found to be similar to the currently approved Moderna COVID-19 vaccines. Positive results were observed in a phase 3 trial evaluating Moderna’s next ...
A new study from the CDC states that there is no data to support an association between the COVID vaccines and sudden cardiac death among previously healthy young persons Vanessa Etienne is an ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the company's ...
, opens new tab said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in line ...